CN116963737A - 抗眩晕化合物及其药物组合物 - Google Patents

抗眩晕化合物及其药物组合物 Download PDF

Info

Publication number
CN116963737A
CN116963737A CN202180074091.1A CN202180074091A CN116963737A CN 116963737 A CN116963737 A CN 116963737A CN 202180074091 A CN202180074091 A CN 202180074091A CN 116963737 A CN116963737 A CN 116963737A
Authority
CN
China
Prior art keywords
vertigo
composition
pharmaceutically acceptable
levoclopidostin
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180074091.1A
Other languages
English (en)
Chinese (zh)
Inventor
尼拉夫·维亚斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amneal Pharmaceuticals LLC
Original Assignee
Kashif Bioscience Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kashif Bioscience Co ltd filed Critical Kashif Bioscience Co ltd
Publication of CN116963737A publication Critical patent/CN116963737A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180074091.1A 2020-10-28 2021-09-10 抗眩晕化合物及其药物组合物 Pending CN116963737A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202021047025 2020-10-28
IN202021047025 2020-10-28
PCT/IN2021/050886 WO2022091118A1 (en) 2020-10-28 2021-09-10 Anti-vertigo compound and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
CN116963737A true CN116963737A (zh) 2023-10-27

Family

ID=81382136

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180074091.1A Pending CN116963737A (zh) 2020-10-28 2021-09-10 抗眩晕化合物及其药物组合物

Country Status (7)

Country Link
US (1) US12685728B2 (enExample)
EP (1) EP4236923A4 (enExample)
JP (1) JP7837967B2 (enExample)
CN (1) CN116963737A (enExample)
AU (1) AU2021368635A1 (enExample)
CA (1) CA3200533A1 (enExample)
WO (1) WO2022091118A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4299059A1 (en) 2022-07-01 2024-01-03 Labelic Analysis, S.L. Composition for the treatment of tinnitus

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0385491A1 (en) * 1989-03-03 1990-09-05 MAGIS FARMACEUTICI S.p.A. Optically active isomer of cloperastine possessing antitussive activity, a process for its preparation and pharmaceutical compositions which contain it
EP0894794A1 (en) * 1997-07-31 1999-02-03 AESCULAPIUS FARMACEUTICI S.r.l. Optical isomers of cloperastine
US20090176792A1 (en) * 2008-01-07 2009-07-09 Auspex Pharmaceuticals, Inc. Substituted dibenzhydrylpiperazines
WO2019004953A1 (en) * 2017-06-29 2019-01-03 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi LEVOCLOPERASTIN FENDIZOATE SUSPENSION HAVING IMPROVED DISSOLUTION AND SUSPENSION CAPACITY

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004269513A (ja) * 2003-02-19 2004-09-30 Rohto Pharmaceut Co Ltd 固形製剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0385491A1 (en) * 1989-03-03 1990-09-05 MAGIS FARMACEUTICI S.p.A. Optically active isomer of cloperastine possessing antitussive activity, a process for its preparation and pharmaceutical compositions which contain it
EP0894794A1 (en) * 1997-07-31 1999-02-03 AESCULAPIUS FARMACEUTICI S.r.l. Optical isomers of cloperastine
US20090176792A1 (en) * 2008-01-07 2009-07-09 Auspex Pharmaceuticals, Inc. Substituted dibenzhydrylpiperazines
WO2019004953A1 (en) * 2017-06-29 2019-01-03 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi LEVOCLOPERASTIN FENDIZOATE SUSPENSION HAVING IMPROVED DISSOLUTION AND SUSPENSION CAPACITY

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JONAS DYHRFJELD-JOHNSEN ET AL.: "Management of peripheral vertigo with antihistamines: New options on the horizon", 《BR J CLIN PHARMACOL》, vol. 85, no. 10, 22 July 2019 (2019-07-22), pages 2255 - 2263, XP071603062, DOI: 10.1111/bcp.14046 *
P. ALIPRANDI ET AL.: "Therapeutic Use of Levocloperastine as an Antitussive Agent: An Overview of Preclinical Data and Clinical Trials in Adults and Children", 《CLIN DRUG INVEST》, 24 August 2012 (2012-08-24), pages 209 - 220 *

Also Published As

Publication number Publication date
CA3200533A1 (en) 2022-05-05
US12685728B2 (en) 2026-07-21
EP4236923A4 (en) 2024-09-25
WO2022091118A1 (en) 2022-05-05
AU2021368635A1 (en) 2023-06-08
EP4236923A1 (en) 2023-09-06
US20230390271A1 (en) 2023-12-07
JP2024506229A (ja) 2024-02-13
JP7837967B2 (ja) 2026-03-31
AU2021368635A9 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
US20220265624A1 (en) Sustained release aminopyridine composition
AU2003240719B2 (en) Ophthalmological use of roflumilast for the treatment of diseases of the eye
US12491179B2 (en) Oral pharmaceutical composition comprising zonisamide and process of preparation thereof
JP2022123032A (ja) エダラボン医薬組成物
JP7837967B2 (ja) 抗眩暈組成物及びその医薬組成物
US20240100077A1 (en) Synergistic nutritional compositions for treating vestibular associated neurodegenerative diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20250714

Address after: new jersey

Applicant after: Xiwanka Research Co.,Ltd.

Country or region after: U.S.A.

Address before: new jersey

Applicant before: Kashif bioscience Co.,Ltd.

Country or region before: U.S.A.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250806

Address after: new jersey

Applicant after: AMNEAL PHARMACEUTICALS LLC

Country or region after: U.S.A.

Address before: new jersey

Applicant before: Xiwanka Research Co.,Ltd.

Country or region before: U.S.A.

TA01 Transfer of patent application right